Literature DB >> 16009032

Bloating and intestinal gas.

Michael P Jones1.   

Abstract

The most common symptoms associated with intestinal gas are eructation, flatulence, abdominal bloating, and distention. Aerophagia is an uncommon cause of eructation in which repetitive air swallowing results in belching, abdominal distention, and increased flatus. Few therapies have been shown to be effective in treating these symptoms. Eructation can be treated by decreasing excessive air swallowing. Occasionally, behavioral therapy and psychotherapy are employed. Bloating, distention, and other gas-related symptoms are common in functional gastrointestinal disorders; however, their pathophysiology is poorly understood. Additionally, evidence supporting the use of various available therapies in treating gas-related symptoms is either absent or poor. Dietary therapy may be effective in patients with excessive gas production. Excessive gas production, identified by increased flatus, may benefit from a low-carbohydrate diet. Many patients with gas-related symptoms have normal gas production but may have either impaired gas transport or transit through the gut or visceral hypersensitivity. Few studies have addressed the treatment of impaired gas transport.

Entities:  

Year:  2005        PMID: 16009032     DOI: 10.1007/s11938-005-0024-x

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  56 in total

1.  Slowing of intestinal transit by fat depends on an ondansetron - sensitive, efferent serotonergic pathway.

Authors:  H C Lin; J H Chen
Journal:  Neurogastroenterol Motil       Date:  2003-06       Impact factor: 3.598

2.  Influence of body posture on intestinal transit of gas.

Authors:  R Dainese; J Serra; F Azpiroz; J-R Malagelada
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

3.  Repetitive eructation as a manifestation of obsessive-compulsive disorder.

Authors:  S J Zella; D L Geenens; J N Horst
Journal:  Psychosomatics       Date:  1998 May-Jun       Impact factor: 2.386

4.  Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth.

Authors:  M Di Stefano; S Malservisi; G Veneto; A Ferrieri; G R Corazza
Journal:  Aliment Pharmacol Ther       Date:  2000-05       Impact factor: 8.171

5.  Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome.

Authors:  S Sen; M M Mullan; T J Parker; J T Woolner; S A Tarry; J O Hunter
Journal:  Dig Dis Sci       Date:  2002-11       Impact factor: 3.199

6.  Does Beano prevent gas? A double-blind crossover study of oral alpha-galactosidase to treat dietary oligosaccharide intolerance.

Authors:  T G Ganiats; W A Norcross; A L Halverson; P A Burford; L A Palinkas
Journal:  J Fam Pract       Date:  1994-11       Impact factor: 0.493

7.  Enzyme replacement therapy for primary adult lactase deficiency. Effective reduction of lactose malabsorption and milk intolerance by direct addition of beta-galactosidase to milk at mealtime.

Authors:  J L Rosado; N W Solomons; R Lisker; H Bourges
Journal:  Gastroenterology       Date:  1984-11       Impact factor: 22.682

8.  Pathologic childhood aerophagia: a recognizable clinical entity.

Authors:  M W Gauderer; T C Halpin; R J Izant
Journal:  J Pediatr Surg       Date:  1981-06       Impact factor: 2.545

9.  Effects of physical activity on intestinal gas transit and evacuation in healthy subjects.

Authors:  Raffaella Dainese; Jordi Serra; Fernando Azpiroz; Juan-R Malagelada
Journal:  Am J Med       Date:  2004-04-15       Impact factor: 4.965

10.  Abnormal colonic fermentation in irritable bowel syndrome.

Authors:  T S King; M Elia; J O Hunter
Journal:  Lancet       Date:  1998-10-10       Impact factor: 79.321

View more
  2 in total

1.  Are bloating and abdominal distention attributed to gas production and visceral sensitivity in irritable bowel syndrome? (Am j gastroenterol 2013;108:1516-1525).

Authors:  Chang Hwan Choi
Journal:  J Neurogastroenterol Motil       Date:  2013-10-07       Impact factor: 4.924

2.  Efficacy and tolerability of α-galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo controlled trial.

Authors:  Giovanni Di Nardo; Salvatore Oliva; Federica Ferrari; Saverio Mallardo; Giovanni Barbara; Cesare Cremon; Marina Aloi; Salvatore Cucchiara
Journal:  BMC Gastroenterol       Date:  2013-09-24       Impact factor: 3.067

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.